centrosomal protein 78Genealiases: C9orf81 · CRDHL · IP63
Q-omics provides the consensus-scored CEP78 profile across patient tissues and cancer cell-line models. CEP78 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CEP78 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, CEP78 RNA expression shows 24,890 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, HNSC, and LSCC as cancer lineages where CEP78 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEP78 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEP78 survival associations across molecular data types. CEP78 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEP78 RNA expression–survival associations across cancer types. High CEP78 expression shows unfavorable associations in MESO, ACC, LIHC, KIRP and SARC, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CEP78 RNA expression.
This table summarizes CEP78 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CEP78. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEP78 shows lower tumor expression in THCA and KIRC and higher tumor expression in HNSC, COAD, STAD and LUSC. The HNSC box plot shows higher CEP78 RNA expression in tumor versus normal tissue (log2 FC = +1.019, t-test p < 0.001).
This table shows molecular features associated with CEP78 in patient tissues and cancer cell lines. In patient samples, CEP78 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CEP78 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
